Atypical antipsychotic-induced weight gain: insights into mechanisms of action (Q37963571)

26 August 2017

Atypical antipsychotic-induced weight gain: insights into mechanisms of action (English)

1 reference

26 August 2017

1 reference

James Edward Mitchell

series ordinal

3

object named as

James E Mitchell

1 reference

26 August 2017

James L Roerig

1

1 reference

PubMed ID

22133326

26 August 2017

Kristine J Steffen

series ordinal

2

1 reference

26 August 2017

1 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

25

1 reference

26 August 2017

12

1 reference

26 August 2017

1035-1059

1 reference

https://scigraph.springernature.com/pub.10.2165/11596300-000000000-00000

26 August 2017

0 references

cites work

Prevalence and trends in obesity among US adults, 1999-2008

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Years of life lost due to obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Metabolic risk factors in drug-naive patients with first-episode psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Prevalence of metabolic syndrome among patients with schizophrenia in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Iloperidone: A new drug for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Biochemical risk factors for development of obesity in first-episode schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A comparison of risperidone-induced weight gain across the age span

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A Double-Blind, Randomized, 8-Week Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of development on olanzapine-associated adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Olanzapine differentially affects 5-HT2Aand2C receptor mRNA expression in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of peripheral administration of 5-hydroxytryptamine (5-HT ) on 2-deoxy-D-glucose-induced hyperphagia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Hypothalamic paraventricular 5-hydroxytryptamine: receptor-specific inhibition of NPY-stimulated eating and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of chronic treatment of olanzapine and haloperidol on peptide YY binding densities in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Gut hormone PYY(3-36) physiologically inhibits food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Inhibition of food intake in obese subjects by peptide YY3-36

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Serotonin 2C receptor agonists and the behavioural satiety sequence in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

What is the mechanism for aripiprazole's effect on reducing olanzapine-associated obesity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Mechanism of the body weight increase induced by systemic sulpiride

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Tamoxifen prevents sulpiride-induced weight gain in female rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The role of dopamine in motivation for food in humans: implications for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Studies on modulation of feeding behavior by atypical antipsychotics in female mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clozapine and dopamine D3 receptor antisense reduce cocaine- and amphetamine-regulated transcript expression in the rat nucleus accumbens shell

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A detailed mapping of histamine H1-receptors in guinea-pig central nervous system established by autoradiography with [125I]iodobolpyramine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Histaminergic H1 and H2 receptors located within the ventromedial hypothalamus regulate food and water intake in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain associated with cinnarizine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Antihistaminic drugs increase feeding, while histidine suppresses feeding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Hypothalamic neuronal histamine modulates ad libitum feeding by rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Involvement of the histaminergic system in leptin-induced suppression of food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

An exploration of the effect of modafinil on olanzapine associated weight gain in normal human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

?-adrenergic insulin release and adrenergic innervation of mouse pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The pharmacology of prazosin, a novel antihypertensive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The role of alpha- and beta-adrenoceptor subtypes in mediating the effects of catecholamines on fasting glucose and insulin concentrations in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Prolonged mild hyperglycemia induces vagally mediated compensatory increase in C-Peptide secretion in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Endocannabinoids in the regulation of appetite and body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of the endogeneous cannabinoid, anandamide, on neuronal activity in rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Endocannabinoids and the control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Role of the endocannabinoid system in regulating cardiovascular and metabolic risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The orexigenic effect of ghrelin is mediated through central activation of the endogenous cannabinoid system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Leptin-regulated endocannabinoids are involved in maintaining food intake

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Risperidone treatment increases CB1 receptor binding in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Dietary influences on peripheral hormones regulating energy intake: potential applications for weight management

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Profiling of energy metabolism in olanzapine-induced weight gain in rats and its prevention by the CB1-antagonist AVE1625.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Long-term treatment with chlorpromazine and haloperidol but not with sulpiride and clozapine markedly elevates neuropeptide Y-like immunoreactivity in the rat hypothalamus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin is a growth-hormone-releasing acylated peptide from stomach

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Unnatural growth hormone-releasing peptide begets natural ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin induces adiposity in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A role for ghrelin in the central regulation of feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Post-prandial decrease of circulating human ghrelin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin enhances appetite and increases food intake in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin and leptin levels in schizophrenic patients treated with antipsychotic monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Decreased levels of ghrelin, cortisol, and fasting blood sugar, but not n-octanoylated ghrelin, in Japanese schizophrenic inpatients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of second generation antipsychotics on leptin and ghrelin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Ghrelin plasma levels during psychopharmacological treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Olanzapine increases plasma ghrelin level in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A prospective study of serum ghrelin levels in patients treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Serum ghrelin concentrations in patients receiving olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Positional cloning of the mouse obese gene and its human homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The function of leptin in nutrition, weight, and physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Serum leptin levels increase rapidly after initiation of clozapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The soluble leptin receptor in olanzapine-induced weight gain: results from a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Plasma leptin and adiposity during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effects of long-term treatment with antipsychotics on serum leptin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Anti-obesity drugs and neural circuits of feeding.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Clozapine-induced weight gain associated with the 5HT2C receptor -759C/T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Polymorphism of the promoter region of the serotonin 5-HT(2C) receptor gene and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Weight gain associated with the -759C/T polymorphism of the 5HT2C receptor and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

-759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

-759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

759C/T genetic variation of 5HT(2C) receptor and clozapine-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Lack of association between the -759C/T polymorphism of the 5-HT2C receptor gene and clozapine-induced weight gain among German schizophrenic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Leptin gene polymorphisms and their phenotypic associations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Meta-analysis of the association of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Do internists, pediatricians, and psychiatrists feel competent in obesity care?: using a needs assessment to drive curriculum design.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Consensus development conference on antipsychotic drugs and obesity and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

A polymorphism in the leptin promoter region (-2548 G/A) influences gene expression and adipose tissue secretion of leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

The Trp64Arg polymorphism of the β3-adrenergic receptor gene and obesity in Chinese subjects with components of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Effect of chronic treatment with clozapine and haloperidol on 5-HT2A and 2C receptor mRNA expression in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596300-000000000-00000

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone

21 January 2018

1 reference

12 December 2020

Pharmacogenetics of antipsychotic-induced side effects

1 reference

12 December 2020

A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.

1 reference

12 December 2020

Overweight and obesity worldwide now estimated to involve 1.7 billion people

1 reference

12 December 2020

Central nervous system control of food intake

1 reference

12 December 2020

Multicenter study with ketotifen (Zaditen) oral drop solution in the treatment of wheezy children aged 6 months to 3 years

1 reference

12 December 2020

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

1 reference

12 December 2020

1 reference

12 December 2020

Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus

1 reference

12 December 2020

Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor.

1 reference

12 December 2020

Reduced satiating effect of d -fenfluramine in serotonin 5-HT 2C receptor mutant mice

1 reference

12 December 2020

The metabolic syndrome and schizophrenia

1 reference

12 December 2020

Association of -2548G/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain

1 reference

12 December 2020

Abnormal correlation between serum leptin levels and body mass index may predict metabolic dysfunction irrespective of the psychopharmacological treatment

1 reference

12 December 2020

Annual medical spending attributable to obesity: payer-and service-specific estimates

1 reference

12 December 2020

Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome

1 reference

12 December 2020

Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.

1 reference

12 December 2020

Metabolic screening in children receiving antipsychotic drug treatment

1 reference

12 December 2020

Asenapine: a review of acute and extension phase data in bipolar disorder

1 reference

12 December 2020

Antipsychotic drugs and obesity: is prolactin involved?

1 reference

12 December 2020

Effects of typical and atypical antipsychotics on neuropeptide Y in rat brain tissue and microdialysates from ventral striatum

1 reference

12 December 2020

Amantadine in the treatment of neuroendocrine side effects of neuroleptics.

1 reference

12 December 2020

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle

1 reference

12 December 2020

Serotonin (5-Hydroxytryptamine), a novel regulator of glucose transport in rat skeletal muscle

1 reference

12 December 2020

Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia

1 reference

12 December 2020

The atypical antipsychotic clozapine impairs insulin secretion by inhibiting glucose metabolism and distal steps in rat pancreatic islets

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Effects of alpha 1-, alpha 2- and beta-adrenoceptor blockers on insulin secretion in the rat

1 reference

12 December 2020

Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats

1 reference

12 December 2020

Metabolic disturbance in first-episode schizophrenia.

1 reference

12 December 2020

Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study.

1 reference

12 December 2020

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors

1 reference

12 December 2020

Adipose tissue leptin production and plasma leptin kinetics in humans

1 reference

12 December 2020

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

1 reference

12 December 2020

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia

1 reference

12 December 2020

Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain

1 reference

12 December 2020

10.2165/11596300-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22133326

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22133326